[go: up one dir, main page]

WO2012006181A3 - Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer - Google Patents

Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer Download PDF

Info

Publication number
WO2012006181A3
WO2012006181A3 PCT/US2011/042436 US2011042436W WO2012006181A3 WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3 US 2011042436 W US2011042436 W US 2011042436W WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cancer
treatment
inhibiting oncogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/042436
Other languages
English (en)
Other versions
WO2012006181A2 (fr
Inventor
Josep M. Llovet
Sara Toffanin
Radoslav Savic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of WO2012006181A2 publication Critical patent/WO2012006181A2/fr
Publication of WO2012006181A3 publication Critical patent/WO2012006181A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des inhibiteurs de micro-ARN et des méthodes pour leur utilisation. Plus particulièrement, l'invention concerne des compositions et des méthodes de traitement de carcinomes hépatocellulaires à l'aide d'inhibiteurs de molécules de micro-ARN surexprimées dans le locus chromosomique 19q13.41 (C19MC).
PCT/US2011/042436 2010-06-29 2011-06-29 Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer Ceased WO2012006181A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35977010P 2010-06-29 2010-06-29
US61/359,770 2010-06-29

Publications (2)

Publication Number Publication Date
WO2012006181A2 WO2012006181A2 (fr) 2012-01-12
WO2012006181A3 true WO2012006181A3 (fr) 2012-04-26

Family

ID=45441752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/042436 Ceased WO2012006181A2 (fr) 2010-06-29 2011-06-29 Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2012006181A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (fr) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification de mutations dans les glycoprotéines d'enveloppe de virus herpès simplex qui permettent ou augmentent le reciblage de vecteur vers de nouveaux récepteurs non-hsv
CA2880649C (fr) 2012-08-01 2023-03-14 Elizabeth MCNALLY Reduction des lesions tissulaires et de la fibrose via la proteine-4 de liaison au tgf beta latent (ltbp4)
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
EP3408382B1 (fr) 2016-01-27 2022-03-23 Oncorus, Inc. Vecteurs viraux oncolytiques et leurs utilisations
AU2017276806A1 (en) * 2016-06-07 2018-12-20 Garvan Institute Of Medical Research Methods of treating neuroblastoma and reagents therefor
MX2018015542A (es) 2016-06-14 2019-10-14 Univ Pittsburgh Commonwealth Sys Higher Education Expresion de proteinas de ligando activadoras de nkg2d para la sensibilizacion de celulas cancerosas para el ataque por celulas inmunocitotoxicas.
RU2758007C2 (ru) 2016-06-30 2021-10-25 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
WO2018047148A1 (fr) * 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
BR112019018272A2 (pt) 2017-03-02 2020-07-28 Youhealth Oncotech, Limited marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CN113917146B (zh) * 2020-07-10 2025-10-03 上海吉凯基因医学科技股份有限公司 人pole2基因的用途及相关产品
CN114480399A (zh) * 2022-03-17 2022-05-13 江苏医药职业学院 降低CPB1基因表达的siRNA、重组载体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RIPPE ET AL.: "The Two Stem Cell MicroRNA Gene Clusters C19MC and miR-371-3 Are Activated by Specific Chromosomal Rearrangements in a Subgroup of Thyroid Adenomas.", PLOS ONE, vol. 5, no. 3, 3 March 2010 (2010-03-03), pages 1 - 11, XP002607044, DOI: doi:10.1371/JOURNAL.PONE.0009485 *
TOFFANIN ET AL.: "MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a", GASTROENTEROLOGY, vol. 140, no. 5, May 2011 (2011-05-01), pages 1618 - 1628 *

Also Published As

Publication number Publication date
WO2012006181A2 (fr) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006181A3 (fr) Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer
WO2012103059A3 (fr) Inhibiteurs de bcl-2/bcl-xl et méthodes thérapeutiques les utilisant
IL205307A0 (en) Targeting micrornas for the treatment of liver cancer
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
WO2009137462A3 (fr) Procédés de traitement de troubles cognitifs à l'aide d'inhibiteurs de l'histone désacétylase
WO2010045345A3 (fr) Procédé de traitement
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
NZ626359A (en) Antisense molecules and methods for treating pathologies
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
WO2013023084A3 (fr) Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
WO2012054862A9 (fr) Agents, compositions et méthodes pour traiter le prurit et des troubles dermiques associés
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2008086182A3 (fr) Utilisation de signatures de gène pour concevoir de nouveaux régimes de traitement de cancer
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
WO2008092099A3 (fr) Compositions et procédés de traitement de malignités hématopoïétiques
HK1210049A1 (en) Combination therapies for treating cancer
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2015032800A3 (fr) Compositions et procédés d'induction de la sénescence dans des cellules cancéreuses
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2013169771A3 (fr) Procédés et compositions pour le pronostic et le traitement de leucémie récurrente
WO2012078519A3 (fr) Dérivés 3-acylidène-2-oxoindole destinés à inhiber la transglutaminase 2
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
ZA201101216B (en) Organoarsenic compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2